Connect Biopharma CEO Barry Quart: Targeting a $5B+ Market with a Next-Gen Asthma & COPD Therapy

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/bf/b0/a0/bfb0a050-9d15-b843-3b2a-ab8a774382fc/mza_17908578731465340111.jpg/600x600bb.jpg

Small Stocks, Big Money

RedChip Companies

115 episodes

1 week ago

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. Founded in 1992, and headquartered in Orlando, Florida, with affiliates in New York and Pittsburgh, RedChip has helped hundreds of companies achieve their capital markets goals. RedChip has been ranked by Inc. magazine as one of the fastest growing privately held investor relations firms in the U.S. RedChip represents 70+ emerging growth companies in a variety of industries including Biotechnology and BioPharma, Business Services, Consumer Goods, High Tech, Mining and Minerals.

Business

RSS

All content for Small Stocks, Big Money is the property of RedChip Companies and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Business

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/38420737/38420737-1689948917073-c156b20bb02fe.jpg

Connect Biopharma CEO Barry Quart: Targeting a $5B+ Market with a Next-Gen Asthma & COPD Therapy

Small Stocks, Big Money

8 minutes 13 seconds

2 weeks ago

Connect Biopharma CEO Barry Quart: Targeting a $5B+ Market with a Next-Gen Asthma & COPD Therapy

🚀 Connect Biopharma (Nasdaq: CNTB) is advancing rademikibart, a next-generation biologic designed to redefine how asthma and COPD are treated — tackling both chronic and acute exacerbations where no biologic currently competes.In this exclusive RedChip Money Report interview, CEO Dr. Barry Quart discusses:✅ How rademikibart targets the IL-4Rα pathway — the same as Dupixent — but with faster onset, superior efficacy, and better safety.✅ The company’s unique positioning in acute exacerbations, a multi-billion-dollar market with no approved biologic therapies.✅ Key upcoming catalysts: topline data from Phase 2 acute studies in 1H 2026 and pharmacology results expected by early next year.✅ CNTB’s strong cash position ($71.8M) and runway into 2027, fully funding its U.S.-focused clinical milestones.✅ How its proven management team — responsible for bringing 16 drugs to FDA approval — is positioning the company for long-term growth.🎬 Watch now to learn why Connect Biopharma could be one of the most compelling small-cap biotech opportunities heading into 2026.Connect Biopharma is a client of RedChip. To learn more about CNTB and to read our full disclosure, visit: CNTBinfo.com.#CNTB #BiotechStocks #SmallCapStocks #AsthmaTreatment #COPD #HealthcareInnovation #Investing #BiotechInvesting #ClinicalTrials #NASDAQ